

amk=20250701:2025070259483

# Årsredovisning

för

## Horizon Therapeutics Sverige AB i likvidation

559338-5965

Räkenskapsår

2024

### Innehållsförteckning

Förvaltningsberättelse	2-3
Resultaträkning	4
Balansräkning	5
Noter	6
Underskrifter	6

### FASTSTÄLLELSEINTYG

Undertecknad styrelseledamot intygar härmed, dels att denna kopia av årsredovisningen överensstämmer med originalet, dels att balans- och resultaträkningen fastställts på årsstämma den 30/6/25. Årsstämman beslöt att godkänna styrelsens förslag till disposition av resultatet.



Emma Bejld Ury  
Likvidator

Horizon Therapeutics Sweden AB i likvidation  
Org.nr 559338-5965

2 (6)

Likvidatorn för Horizon Therapeutics Sweden AB i likvidation avger följande årsredovisning för räkenskapsåret 2024.

Årsredovisningen har upprättats i svenska kronor, SEK. Om inget annat anges redovisas alla belopp i hela SEK. Uppgifter inom parentes avser föregående år.

## Förvaltningsberättelse

### Verksamheten

#### Allmänt om verksamheten

Bolaget har bedrivit marknadsförings- och detaljhandelstjänster för att stödja försäljningen av läkemedel i Sverige.

Företaget har sitt säte i Stockholm.

#### Väsentliga händelser under räkenskapsåret

Inga händelser har inträffat under räkenskapsåret.

Flerårsöversikt (kr)	2024	2023
Nettoförsäljning	0	0
Resultat efter finansiella poster	-44 556	-34 680
Soliditet (%)	3,3	10,2

För definitioner av nyckeltal, se not 1 Redovisningsprinciper.

### Förändringar i eget kapital

	Aktie- kapital	Balanserat resultat	Årets resultat	Totalt
Insatt aktiekapital	25 000	97 158	-34 680	87 478
Disposition enligt beslut av årsstämman:				
Balanseras i ny räkning		-34 680	34 680	-
Årets resultat			-44 556	-44 556
<b>Belopp vid årets utgång</b>	<b>25 000</b>	<b>62 478</b>	<b>-44 556</b>	<b>42 922</b>

Ej återbetalda villkorade aktieägartillskott uppgår per balansdagen till 100 000 kr (2023: 100 000 kr).

Horizon Therapeutics Sweden AB i likvidation  
Org.nr 559338-5965

3 (6)

### Resultatdisposition

Likvidatorn föreslår att till förfogande stående vinstmedel (kr):

Balanserad vinst	62 478
Årets förlust	-44 556
	<b>17 922</b>
disponeras så att	
i ny räkning överföres	17 922
	<b>17 922</b>

Bolagets resultat och ställning i övrigt framgår av efterföljande resultat- och balansräkning med noter.

ank=20250701;2025070259485

Horizon Therapeutics Sweden AB i likvidation  
Org.nr 559338-5965

4 (6)

## Resultaträkning

	Not	2024-01-01 -2024-12-31	2023-01-01 -2023-12-31
<b>Rörelseresultat</b>			
Övriga rörelseintäkter		391 743	493 690
<b>Summa rörelseintäkter</b>		<b>391 743</b>	<b>493 690</b>
<b>Rörelsekostnader</b>			
Övriga externa kostnader		-391 743	-490 586
<b>Summa rörelsekostnader</b>		<b>-391 743</b>	<b>-490 586</b>
<b>Rörelseresultat</b>	2	-	<b>3 105</b>
<b>Finansiella poster</b>			
Övriga ränteintäkter och liknande resultatposter	3	1 319	801
Räntekostnader och liknande resultatposter	4	-45 875	-38 586
<b>Summa finansiella poster</b>		<b>-44 556</b>	<b>-37 785</b>
<b>Resultat efter finansiella poster</b>		<b>-44 556</b>	<b>-34 680</b>
<b>Resultat före skatt</b>		<b>-44 556</b>	<b>-34 680</b>
<b>Årets resultat</b>		<b>-44 556</b>	<b>-34 680</b>

ank=20250701,2025070259486

Horizon Therapeutics Sweden AB i likvidation  
Org.nr 559338-5965

5 (6)

<b>Balansräkning</b>	<b>Not</b>	<b>2024-12-31</b>	<b>2023-12-31</b>
<b>TILLGÅNGAR</b>			
<b>Omsättningstillgångar</b>			
<i>Kortfristiga fordringar</i>			
Fordringar hos koncernföretag		201 108	230 283
Övriga fordringar		34 321	32 520
<b>Summa kortfristiga fordringar</b>		<b>235 429</b>	<b>262 803</b>
<i>Kassa och bank</i>			
Kassa och bank		1 082 609	598 495
<b>Summa kassa och bank</b>		<b>1 082 609</b>	<b>598 495</b>
<b>Summa omsättningstillgångar</b>		<b>1 318 038</b>	<b>861 298</b>
<b>SUMMA TILLGÅNGAR</b>		<b>1 318 038</b>	<b>861 298</b>
<b>EGET KAPITAL OCH SKULDER</b>			
<b>Eget kapital</b>			
<i>Bundet eget kapital</i>			
Aktiekapital		25 000	25 000
<b>Summa bundet eget kapital</b>		<b>25 000</b>	<b>25 000</b>
<i>Fritt eget kapital</i>			
Balanserat resultat		62 478	97 158
Årets resultat		-44 556	-34 680
<b>Summa fritt eget kapital</b>		<b>17 922</b>	<b>62 478</b>
<b>Summa eget kapital</b>		<b>42 922</b>	<b>87 478</b>
<b>Kortfristiga skulder</b>			
Skulder till koncernföretag		1 275 116	773 820
<b>Summa kortfristiga skulder</b>		<b>1 275 116</b>	<b>773 820</b>
<b>SUMMA EGET KAPITAL OCH SKULDER</b>		<b>1 318 038</b>	<b>861 298</b>

ank=20250701;2025070259487

**Noter****Not 1 Redovisningsprinciper****Allmänna upplysningar**

Årsredovisningen är upprättad i enlighet med årsredovisningslagen och Bokföringsnämndens allmänna råd (BFNAR 2016:10) om årsredovisning i mindre företag.

**Nyckeltalsdefinitioner**

Nettoomsättning

Rörelsens huvudintäkter, fakturerade kostnader, sidointäkter samt intäktskorrigeringar.

Resultat efter finansiella poster

Resultat efter finansiella intäkter och kostnader men före bokslutsdispositioner och skatter.

Soliditet (%)

Justerat eget kapital (eget kapital och obeskattade reserver med avdrag för uppskjuten skatt) i procent av balansomslutningen.

**Not 2 Genomsnittligt antal anställda**

	2024	2023
Sverige	0	0

**Not 3 Övriga ränteintäkter och liknande resultatposter**

	2024	2023
Övriga ränteintäkter	1 319	801
	<b>1 319</b>	<b>801</b>

**Not 4 Räntekostnader och liknande resultatposter**

	2024	2023
Räntekostnader, koncernföretag	-39 267	-19 592
Räntekostnader, övrigt	-8 244	-9
Valutakursförändring	1 636	-18 985
	<b>-45 875</b>	<b>-38 586</b>


**Not 5 Uppgifter om moderbolag**

Bolaget är helägt av Horizon Therapeutics Ireland DAC med organisationsnummer 376554 och registrerat säte i Dublin, Irland. Yttersta moderbolag är Amgen Inc med organisationsnummer 2106150 och registrerat säte i Thousand Oaks, USA.

**Not 6 Väsentliga händelser efter räkenskapsårets utgång**

Den 21 januari 2025 beslutade en extra bolagsstämma om likvidation av bolaget per den 21 januari 2025. Den 10 februari 2025 utsåg Bolagsverket advokat Emma Berglund Uväng till likvidator.

Stockholm, dagen som står på min elektroniska signatur

Signed by:  
  
 Emma Berglund Uväng  
 BBB35636B61342E...  
 Likvidator

Adress:  
  
 Emma Berglund Uväng

**Certificate Of Completion**

Envelope Id: 989D6493-9819-44E0-9641-83FC27244F04  
 Subject: Complete with Docusign: Horizon Therapeutics Sweden AB 2024 Final.pdf  
 Matter No.: 514663-602  
 Source Envelope:  
 Document Pages: 6  
 Certificate Pages: 5  
 AutoNav: Enabled  
 Envelopeld Stamping: Enabled  
 Time Zone: (UTC+01:00) Brussels, Copenhagen, Madrid, Paris

Status: Completed

Envelope Originator:  
 Chris Engzell  
 Ruseløkkveien 14  
 Oslo, Oslo 0201  
 chris.engzell@schjodt.com  
 IP Address: 83.241.187.122

**Record Tracking**

Status: Original  
 6/27/2025 2:47:47 PM

Holder: Chris Engzell  
 chris.engzell@schjodt.com

Location: DocuSign

**Signer Events**

Emma Berglund Uväng  
 emma.berglund@schjodt.com  
 Security Level: Email, Account Authentication  
 (None), Digital Certificate

**Signature**

Signed by:  
  
 BBB3583881342E...

**Timestamp**

Sent: 6/27/2025 2:48:26 PM  
 Viewed: 6/27/2025 2:53:05 PM  
 Signed: 6/27/2025 2:55:06 PM

**Signature Provider Details:**

Signature Type: DocuSign Protect & Sign (Client  
 ID: dde5e85d-4085-40b6-8785-da3ccd16d81e)

Signature Adoption: Pre-selected Style  
 Using IP Address: 83.241.187.122

Signature Issuer: DocuSign Cloud Signing CA -  
 S11

Signature Provider Location: https://ps-ws.dsf.docusi  
 gn.net/ds-server/s/noauth/psm/  
 tsp/sign/psm-docusign/2PSIGAES/SERVID02

**Authentication Details****Identity Verification Details:**

Workflow ID: 6b2d3c20-6e49-4c91-b1d1-5bd580d827b6  
 Workflow Name: DocuSign ID Verification for EU Advanced  
 Workflow Description: The recipient will need to identify themselves with a valid government ID.  
 Identification Method: Electronic ID  
 Type of Electronic ID: BankID Sweden  
 Transaction Unique ID: 45bb85ea-fb78-50fe-832c-86993237b23d  
 Country or Region of ID: SE  
 Result: Passed  
 Performed: 6/27/2025 2:52:51 PM

**Electronic Record and Signature Disclosure:**

Accepted: 6/27/2025 2:53:05 PM  
 ID: 78cf25e6-cd6a-406c-b2e4-9c305afa3da6

**In Person Signer Events**

Signature

Timestamp

**Editor Delivery Events**

Status

Timestamp

**Agent Delivery Events**

Status

Timestamp

**Intermediary Delivery Events**

Status

Timestamp

**Certified Delivery Events**

Status

Timestamp

**Carbon Copy Events**

Status

Timestamp

**Witness Events**

Signature

Timestamp

**Notary Events**

Signature

Timestamp

enr=202507012025070259489

ark=202507012025070259490

**Envelope Summary Events**

Envelope Sent  
Certified Delivered  
Signing Complete  
Completed

**Status**

Hashed/Encrypted  
Security Checked  
Security Checked  
Security Checked

**Timestamps**

6/27/2025 2:48:26 PM  
6/27/2025 2:53:05 PM  
6/27/2025 2:55:06 PM  
6/27/2025 2:55:06 PM

**Payment Events**

**Status**

**Timestamps**

**Electronic Record and Signature Disclosure**

## **ELECTRONIC RECORD AND SIGNATURE DISCLOSURE**

From time to time, Advokatfirmaet Schjødt AS (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

### **Getting paper copies**

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

### **Withdrawing your consent**

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

### **Consequences of changing your mind**

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

### **All notices and disclosures will be sent to you electronically**

ank=20250701:2025070259491

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

**How to contact Advokatfirmaet Schjødt AS:**

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: [license@schjodt.com](mailto:license@schjodt.com)

**To advise Advokatfirmaet Schjødt AS of your new email address**

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at [license@schjodt.com](mailto:license@schjodt.com) and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

**To request paper copies from Advokatfirmaet Schjødt AS**

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to [license@schjodt.com](mailto:license@schjodt.com) and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

**To withdraw your consent with Advokatfirmaet Schjødt AS**

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to [license@schjodt.com](mailto:license@schjodt.com) and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

### **Required hardware and software**

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

### **Acknowledging your access and consent to receive and sign documents electronically**

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Advokatfirmaet Schjødt AS as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Advokatfirmaet Schjødt AS during the course of your relationship with Advokatfirmaet Schjødt AS.